Directors

haydon_sm

Philip G. Haydon, Ph.D.

President and co-Founder

Philip Haydon is President of GliaCure and the Annetta and Gustav Grisard Professor and Chair in the Department of Neuroscience at Tufts. In 1994 Phil Haydon’s laboratory discovered that astrocytes can release the chemical transmitter glutamate in response to receptor-induced Ca2+ elevations and that this glial-mediated signal can activate neighboring neurons. In 1999 he coined the expression “the tripartite synapse” to recognize the important role that astrocytes play in tuning and modulating synaptic transmission. More recently Phil Haydon has begun studies on microglia and has emphasized identification of the mechanisms regulating phagocytosis by this subtype of glial cell. He has discovered the importance of reactivation of the microglial phagocytotic pathway that normally declines in Alzheimer’s disease. In addition to his academic background Phil Haydon has significant experience in commercial enterprises. He was a founding partner in three small businesses, including Prairie Technologies, Inc. This company, founded in 1995, sprang from Phil’s need for new imaging technology to optimize his neuroscience research.

Szulczewski_sm_1

Rudy Schreiber, Ph.D.

Vice President of Translational Research and Development

Dr. Rudy Schreiber serves as Vice President for Translational Research and Discovery for GliaCure. He heads an independent consulting group, Suadeo Drug Discovery Consulting, LLC. Prior to formation of this consulting company, Dr. Schreiber held positions at Roche, Sepracor and Evotec, where he developed expertise and leadership in behavioral studies with a specific focus on CNS projects. His experience as a scientist and as a project and team leader in various pharma groups allows him to provide invaluable support to GliaCure’s development program.

haydon_sm

Alan Barber

Chief Financial Officer

Alan T. Barber is founder and Managing Director of the Prestar Group. A seasoned financial executive, Alan has over 30 years of hands on financial and operating business experience with a proven record of integrity and results-oriented leadership. Alan began his career as a CPA with Coopers & Lybrand. As a partner in Coopers Dallas and Tokyo offices his responsibilities included Mergers & Acquisitions Practice Leader for the Southwest Region and Partner-in-Charge of the Foreign Financial Services practice for Japan. After completing seventeen years in public accounting, Alan spent twelve years as the CFO of various venture backed emerging life science and software companies. These included Ergo Science, Medical Foods, MyWay.com, Innovation Chain, Omnisonics Medical Technology, and BioTrove. In the role of CFO he successfully assisted companies in IPOs and private financings, mergers & acquisitions, strategic partnerships, business planning, systems installations and creatively solving a broad range of business and operating problems. Alan received a Bachelor of Science Degree in Accounting from the Florida State University Rovetta College of Business.

haydon_sm

Philip G. Haydon, Ph.D.

President and co-Founder

Philip Haydon is President of GliaCure and the Annetta and Gustav Grisard Professor and Chair in the Department of Neuroscience at Tufts. In 1994 Phil Haydon’s laboratory discovered that astrocytes can release the chemical transmitter glutamate in response to receptor-induced Ca2+ elevations and that this glial-mediated signal can activate neighboring neurons. In 1999 he coined the expression “the tripartite synapse” to recognize the important role that astrocytes play in tuning and modulating synaptic transmission. More recently Phil Haydon has begun studies on microglia and has emphasized identification of the mechanisms regulating phagocytosis by this subtype of glial cell. He has discovered the importance of reactivation of the microglial phagocytotic pathway that normally declines in Alzheimer’s disease. In addition to his academic background Phil Haydon has significant experience in commercial enterprises. He was a founding partner in three small businesses, including Prairie Technologies, Inc. This company, founded in 1995, sprang from Phil’s need for new imaging technology to optimize his neuroscience research.

Dewey_Walter_sm

Walter E. Dewey, C.F.A.

Walter Dewey received his B.B.A. in Finance in 1983 from the University of Wisconsin-Madison. He is Vice President and Portfolio Manager at Madison Investment Advisors, specializing in investment and wealth management services for families and individuals with high net worth. Prior to joining Madison Investment Advisors in 2013, he spent 5 years at Reinhart Partners as senior Portfolio Manager and Principal and 21 years in various investment-related activities with US Bancorp and its predecessors. In addition to his professional activities, he has been involved in numerous early stage companies as an investor and board member. Walter currently serves on the boards of Quintessence Biosciences, Broadjam, Inc, and Platypus Technologies, and was previously on the board of Nerites before its sale to a public company. He received his Chartered Financial Analyst (CFA) designation in 1989.

Szulczewski_sm_1

Michael Szulczewski B.S.E.E.

GliaCure Vice President Michael Szulczewski received his BSEE with a major option in integrated circuits and electron devices in 1981 from the University of Wisconsin – Madison. Mike was also the President and co-Founder of Prairie Technologies, Inc. Based in Madison, Wisconsin, Prairie manufactures, sells and supports laser microscopy instruments worldwide for use in cell biology and neurobiology research. Founded in 1995 Prairie was acquired by the Bruker Corporation in September 2013. Prior to founding Prairie, Mike held various positions with large corporations in engineering, sales, product management and general business.

Joseph S. Zakrzewski, M.B.A.

Mr. Zakrzewski is currently the Chairman of Onxeo. He has over 25 years of experience as an executive in the biotechnology and pharmaceutical industry, serving on the Board of Directors of publicly held companies Acceleron Pharmaceuticals, Amarin Pharmaceuticals, Insulet Corporation, and Onxeo. Mr Zakrzewski also serves on the board of a number of privately held companies, is advisor to a number of entities, and is involved in a number of philanthropic activities. He was Chairman and CEO of Amarin Pharmaceuticals, successfully developing and launching Vascepa®. Mr. Zakrzewski served as a Venture Partner with Orbimed, was Chairman, President and CEO of Xcellerex, and served as the Chief Operating Officer of Reliant Pharmaceuticals. From 1988 to 2004, Mr. Zakrzewski served in a variety of executive level capacities at Eli Lilly & Company including R&D, manufacturing, finance and business development focused on Lilly’s biotechnology & protein business. His most recent position was Vice President, Corporate Business Development, where he had global responsibility for all business development activities on a worldwide basis. Mr. Zakrzewski received a BS in Chemical Engineering in 1986, an MS in Biochemical Engineering from Drexel University in 1988, and an MBA in Finance in 1992 from Indiana University.

Reinhart_sm

Peter H. Reinhart, Ph.D

Founding Director, the Institute for Applied Life Sciences (IALS), UMass Amherst Dr. Reinhart received his B.Sc. and Ph.D. in Biochemistry from the Australian National University. He went on to carry out his postdoctoral training in Neurobiology at the University of Tuebingen, Germany, and was then a research fellow at Brandeis University. He was a faculty member at Duke University Medical Center for 12 years, then took on the role as Vice President, Neurodegeneration at Cogent Neuroscience, moving then to oversee Neurodegeneration Research at Wyeth Pharmaceuticals and Pfizer, focusing on Alzheimer’s disease, Parkinson’s disease, stroke regeneration, and ALS programs. During his six-year tenure at Wyeth/Pfizer, Dr. Reinhart delivered numerous small molecule and biomolecule drug candidates into clinical development. In February 2010 Dr. Reinhart joined Proteostasis as President and Chief Scientific Officer before accepting the post as Head of Discovery and New Product Development at Alzheon. In February 2015 Dr. Reinhart became the founding director of the Institute for Applied Life Sciences at UMass Amherst, where he brings to bear his dual expertise in academia and industry to accelerate life sciences development and to promote collaborations between the institution and the pharma inductry. Dr. Reinhart has authored more than 90 publications, serves as a scientific reviewer for Science, Neuron, Nature Drug Discovery, Journal of Neuroscience, and Molecular Pharmacology, is on the Scientific Advisory Board of the Michael J. Fox Foundation for Parkinson’s Research, and contributes to numerous government and foundation grant review boards.

Khoury_sm

Joseph El Khoury, M.D.

Clinician and Associate Professor, Massachusetts General Hospital and Harvard Medical School. Joseph El Khoury received his M.D. from the American University of Beirut and his clinical training in Internal Medicine and Infectious Diseases at Beth Israel Hospital in New York and Massachusetts General Hospital (MGH) in Boston. After completing his postdoctoral studies at Columbia University in New York and at MGH and Harvard Medical School he went on to become a faculty member at Harvard Medical School in 2002. He is the principal investigator for the laboratory for Innate Immunity and Neuroimmunology at the center for Immunology and Inflammatory diseases at MGH. He is also a physician with an active clinical practice at MGH. Dr. El Khoury is an expert neuroimmunologist who has dedicated a substantial part of his career to the study of microglia, the innate immune cells of the brain with a focus on the role on these cells in aging and Alzheimer’s disease. He was the first to identify a microglial receptor for β-amyloid, the pathogenic protein that accumulates in Alzheimer’s brain. He also studies the pathways that regulate microglial accumulation and activation in this disease and is the author of several seminal papers and book chapters in the field. Dr. El Khoury has received awards from the American Federation for Medical Research and the American Health Assistance foundation and is a member of the scientific advisory council for the American Federation for Aging Research. His research is currently supported by several grants from the National Institutes of Health where he also serves as a grant reviewer.

Tononi_sm

Giulio Tononi, M.D., Ph.D

Professor, University of Wisconsin Madison Giulio Tononi received his medical degree and specialized in Psychiatry at the University of Pisa, Italy. After serving as a medical officer in the Army, he obtained a Ph.D. in neuroscience as a fellow of the Scuola Superiore, based on his work on sleep regulation. From 1990 to 2000 he was at The Neurosciences Institute, first in New York and then in San Diego. He is currently Professor of Psychiatry, Distinguished Professor in Consciousness Science, and the David P. White Chair in Sleep Medicine at the University of Wisconsin, Madison. In 2005, Dr. Tononi received the NIH Director’s Pioneer Award for his work on sleep mechanism and function. Dr. Tononi is an award-winning psychiatrist and neuroscientist whose main focus has been the scientific understanding of consciousness. His integrated information theory is a comprehensive theory of what consciousness is, how it can be measured, and how it is realized in the brain. The theory is being tested with neuroimaging, transcranial magnetic stimulation, and computer models. His work also focuses on understanding the function of sleep. He and his collaborators study species ranging from fruit flies to humans, from the molecular and cellular level to the systems level. This research has led to the synaptic homeostasis hypothesis, according to which sleep is needed to renormalize synapses, counteracting the progressive increase in synaptic strength that occurs during wakefulness due to learning. The hypothesis has implications for understanding the effects of sleep deprivation and for developing diagnostic and therapeutic approaches to sleep disorders and neuropsychiatric disorders.